The aim of this study was to evaluate the immune responses to intranasal and intrapulmonary vaccinations with the attenuated Mycoplasma hyopneumoniae (Mhp) 168 strain in the local respiratory tract in pigs. Twenty-four pigs were randomly divided into 4 groups: an intranasal immunization group, an intrapulmonary immunization group, an intramuscular immunization group and a control group. The levels of local respiratory tract cellular and humoral immune responses were investigated. The levels of interleukin (IL)-6 in the early stage of immunization (P<0.01), local specific secretory IgA (sIgA) in nasal swab samples (P<0.01); and IgA- and IgG-secreting cells in the nasal mucosa and trachea were higher after intranasal vaccination (P<0.01) than in the control group. Interestingly, intrapulmonary immunization induced much stronger immune responses than intranasal immunization. Intrapulmonary immunization also significantly increased the secretion of IL-6 and local specific sIgA and the numbers of IgA- and IgG-secreting cells. The levels of IL-10 and interferon-γ in the nasal swab samples and the numbers of CD4(+) and CD8(+) T lymphocytes in the lung and hilar lymph nodes were significantly increased by intrapulmonary immunization compared with those in the control group (P<0.01). These data suggest that intrapulmonary immunization with attenuated Mhp is effective in evoking local cellular and humoral immune responses in the respiratory tract. Intrapulmonary immunization with Mhp may be a promising route for defense against Mhp in pigs.
The aim of this study was to evaluate the immune responses to intranasal and intrapulmonary vaccinations with the attenuated Mycoplasma hyopneumoniae (Mhp) 168 strain in the local respiratory tract in pigs. Twenty-four pigs were randomly divided into 4 groups: an intranasal immunization group, an intrapulmonary immunization group, an intramuscular immunization group and a control group. The levels of local respiratory tract cellular and humoral immune responses were investigated. The levels of interleukin (IL)-6 in the early stage of immunization (P<0.01), local specific secretory IgA (sIgA) in nasal swab samples (P<0.01); and IgA- and IgG-secreting cells in the nasal mucosa and trachea were higher after intranasal vaccination (P<0.01) than in the control group. Interestingly, intrapulmonary immunization induced much stronger immune responses than intranasal immunization. Intrapulmonary immunization also significantly increased the secretion of IL-6 and local specific sIgA and the numbers of IgA- and IgG-secreting cells. The levels of IL-10 and interferon-γ in the nasal swab samples and the numbers of CD4(+) and CD8(+) T lymphocytes in the lung and hilar lymph nodes were significantly increased by intrapulmonary immunization compared with those in the control group (P<0.01). These data suggest that intrapulmonary immunization with attenuated Mhp is effective in evoking local cellular and humoral immune responses in the respiratory tract. Intrapulmonary immunization with Mhp may be a promising route for defense against Mhp in pigs.
Mycoplasmal pneumonia of swine, caused by Mycoplasma hyopneumoniae
(Mhp), is one of the most common and economically most important diseases
of swine. The primary mycoplasmal infection often becomes complicated by secondary bacterial
infections with Pasteurella multocida or Actinobacillus
pleuropneumoniae or by viral infections with porcine circovirus type
2, porcine parvovirus and porcine reproductive and respiratory
syndrome virus (PRRSV), resulting in more severe lung lesions and production
losses, including slow growth and poor feed conversion. The major routes of entry for the
Mhp pathogen are the mucosal surfaces of the respiratory tract, and it
spreads throughout herds by airborne transmission. The establishment of immune responses in
the respiratory tract mucosa may play a critical role in preventing Mhp
invasion [2]. In the upper respiratory tract, lymphoid
tissues are present in the pig nose cavity, especially in the pharyngeal tonsils and tubal
tonsils located in the posterior area. Intranasal vaccination could induce the production of
cytokines and antibodies by these lymphoid tissues [11]. Recent studies have shown that intranasal immunization with an attenuated virus
can induce effective immune responses, including against pseudorabies virus
(PRV) and PRRSV [4,
10, 24].Recently, an attenuated Mhp 168 strain vaccine has been widely used to
control Mhp spread in China. However, the protective effect of intramuscular
immunization may be less than satisfactory because the pathogen only proliferates in the
epithelium of the respiratory tract, so intramuscular immunization has been replaced with
intrapulmonary immunization [26]. Intrapulmonary
vaccination has considerable potential as a route of delivery [18], because it can lead to the stimulation of IgG-mediated immune protection in the
alveoli and mucosal secretory IgA (sIgA)-mediated immune protection in the conducting airways
[12]. It is easier for the lung to elicit maximal
local immune responses with low levels of antigen because it is located in the lower
respiratory tract, which is sterile under ordinary conditions. Wee et al.
[22] found that intrapulmonary immunization with
extremely low antigen doses (0.04 g influenza antigen) induced serum antibody levels
equivalent to those resulting from the current human vaccine equivalent (15 g antigen
influenza without adjuvant, administered subcutaneously). However, few researchers have
ventured into the field of intrapulmonary vaccination.Intranasal vaccination and intrapulmonary vaccination induce upper respiratory tract and
lower respiratory tract immune responses, respectively. However, the exact immunological
mechanisms of this attenuated Mhp 168 strain vaccine are not very clear. In this study, we
inoculated piglets with the attenuated M. hyopneumoniae 168 strain vaccine by
intranasal, intrapulmonary and intramuscular routes. The local mucosal and cell-mediated
immune responses were evaluated, and then, the intranasal and intrapulmonary vaccinations were
compared.
MATERIALS AND METHODS
Vaccine strain: The attenuated Mhp 168 strain (titer 1 ×
106 color changing units (CCU)/ml) was purchased from Nanjing
Tianbang Bio-industry Co. (Nanjing, PR China). The safety of the attenuated
Mhp 168 strain was certified by an animal regression test [26].Animals and experimental design: Twenty-four newborn cross-bred (Landrace
× Large Yorkshire) piglets, from 4 litters were housed with their sow at Sentai
Hogpen Farm (Anhui, PR China), which was free of Mhp. The piglets were
healthy and unvaccinated with any Mhp vaccines, and they were fed without
antibiotics. The piglets were divided randomly into 4 groups (each group consisted of 6
pigs); and were immunized as shown in Table
1. Among them, 6 piglets from Group IP received 1 ml
(106 CCU) Mhp 168 strain each by the intrapulmonary through
the Su-qi acupoint between the 2nd and 3rd ribs behind the right scapula [26].
Table 1.
Experimental groups and administration strategies
Group
Placebo antigen(no adjuvants)
Age atadministration
Route ofadministration
Control
Phys saline
7 and 10 days
Intranasal
Mhp-IM
Mhp 168, 106 CCU
7 days
Intramuscular
Mhp-IN
Mhp 168, 106 CCU
7 and 10 days
Intranasal
Mhp-IP
Mhp 168, 106 CCU
7 days
Intrapulmonary
Collection and preparation of samples: Nasal swabs were collected from
pigs on 0, 3, 5, 7, 14, 21, 28 and 35 days post immunization (DPI) by inserting cotton wool
swabs deeply into 2 nasal cavities. Each swab was placed in a tube that contained 1
ml of sterile phosphate-buffered saline (PBS) and stored at 4–8°C
overnight. The swab suspensions were centrifuged at 10,000 g for 5 min, and the supernatant
was collected for detection of anti-Mhp sIgA and cytokines IL-6, IL-10 and IFN-γ. Nasal
swabs from specific pathogen-free (SPF) piglets were collected and used as negative controls
in a sIgA enzyme-linked immunosorbent assay (ELISA), and piglets challenged artificially
with Mhp were used as the positive control.All pigs were slaughtered at 6 weeks after the first vaccination. Tissue samples from the
nasal mucosa (posterior part of nasal cavity, around pharyngeal tonsil and the tubal
tonsil), trachea, tracheal bifurcation, lung and hilar lymph node (HLN) were taken
respectively and fixed in Bouin’s liquid or liquid nitrogen for histological and
immunohistochemical detection. Our study was carried out according to China’s animal welfare
guidelines.IL-6, IL-10 and IFN-γ detection: PorcineIL-6, IL-10 and IFN-γ in nasal
secretions were detected at 3 and 5 DPI following the manufacturer’s instructions for
porcineIL-6 (Cat. no.: P6000, R&D Systems, Minneapolis, MN, U.S.A.); and IL-10 (Cat.
no.: P1000, R&D Systems) ELISA kits and for a pig IFN-γ Platinum ELISA Kit (Cat. no.:
BMS671, eBioscience, San Diego, CA, U.S.A.).Immunohistochemical examination for CD4: The fixed samples were embedded in paraffin and sectioned at 8
µm thickness, and then, all were deparaffinized to water. The sections
were neutralized by 3% H2O2 in PBS for 10 min; and then rinsed in
distilled water for 15 min. The sections were then immersed in 0.01 M citric acid salt
buffer with a liquid hydrogen ion index of 6.0. The sections were boiled in a microwave oven
and then cooled, and this process was repeated 5 min later, followed by a rinse in PBS (pH
7.2–7.6) for 15 min. The sections were treated with 5% BSA in PBS for 20 min to block
nonspecific binding, stained separately with mouse anti-porcineCD4 (or CD8) antibody
(Codes: APG420 and APG 820, Antigenix America, Huntington Station, NY, U.S.A.) at 4°C
overnight; and then rinsed in PBS (pH 7.2–7.6) for 15 min. Next, sections were incubated
with goat anti-mouse IgG-Biotin (Boster, Wuhan, PR China) for 20 min at 37°C and rinsed in
PBS (pH 7.2–7.6) for 20 min. The sections were visualized with metal-enhanced
diaminobenzidine (DAB; Sigma). Incubation was performed in a moist chamber. Control staining
was carried out simultaneously, in which the first antibody was replaced with normal mouse
serum. The sections were observed under an Olympus BH-2 microscope, and 10 different fields
were chosen per section, with 5 sections per pig in each group; the data for the positive
cells were calculated per region. The regions that contained CD4+ and
CD8+ T lymphocytes were counted by the Image Pro-plus analysis program
(Cambridge, U.K.), and the results were used in the statistical analysis.Immunohistochemical examination for IgA- and IgG-secreting cells: The
experimental process was the same as that above, except that the mouse anti-porcineCD4 (or
CD8) antibody was replaced with a rabbit anti-porcine IgA (or IgG) antibody and the goat
anti-mouse IgG-Biotin was replaced with staphylococcal protein A-horseradish peroxidase
(SPA-HRP).Specific sIgA detection: Anti-Mhp sIgA was detected by indirect ELISA as
an estimate of mucosal immunity levels at 7, 14, 21, 28 and 35 DPI. Briefly, polystyrene
plates were coated overnight at 4°C with 5 µg per well of Mhp P97R1 protein
(supplied by Jiangsu Academy of Agricultural Sciences, China) diluted in
carbonate-bicarbonate buffer (pH 9.6) [5]. Then, the plates were blocked with 1% BSA in PBS. After three PBS-T washes,
100 µl swab suspensions, in triplicate, were added to the plates. The
samples were incubated for 2 hr at 37°C and washed three times with PBS-T, goat anti-pig IgA
(Cat. no.: A100–102P, Bethyl Laboratories, Montgomery, TX, U.S.A.) diluted 1:8,000 in 1% BSA
was added, and samples were incubated at 37°C for 1 hr. After repeated washes, rabbit
anti-goat IgG conjugated with horseradish peroxidase (1:10,000 in 1% BSA) was added, and the
samples were incubated at 37°C for 1 hr. After three PBS-T washes, a colorimetric reaction
was induced by the addition of 100 µl of the chromogenic substrate (0.1
mg/ml tetramethylbenzidine (TMB; Sigma), 100 mM acetate buffer, pH 5.6,
and 1 mM urea hydrogen peroxide) for 10 min at 37°C. Color development was stopped
with 50 µl H2SO4 (2
M), and the optical density at 450 nm (OD450) was recorded
using an universal ELx800 Absorbance Reader (Bio-Tek Instruments, Inc., Winooski, VT,
U.S.A.). The experimental conditions given above were optimized to determine the highest
OD450 ratio between positive and negative samples (P/N value). The S/P value was calculated
by the following formula: S/P = (OD450 of sample − OD450 of negative
control)/(OD450 of standard positive control − OD450 of negative control).Statistics: All data were expressed as the mean ± SEM. Experimental values
were analyzed by analysis of variance (ANOVA). In the figures, the level of significance is
identified by the P value. Capital letters indicate differences at
P<0.01, and small letters indicate differences at
P<0.05.
RESULTS
Changes in the cytokines IL-6, IL-10 and IFN-γ: As shown in Fig. 1, intranasal immunization and intrapulmonary immunization with the attenuated
Mhp(without adjuvant) significantly increased the secretion of IL-6 and
IFN-γ at 3 DPI compared with the control group
(P<0.05 and P<0.01, respectively), and intramuscular
immunization with Mhp increased the secretion of IL-10
(P<0.01). However, the secretion of IL-10 after intranasal immunization
or intrapulmonary immunization did not differ from that in the control group. The level of
IFN-γ after immunization via the intrapulmonary route was much higher than after
immunization via the other routes (P<0.01). Intrapulmonary immunization
with Mhp significantly increased the secretion of IL-6, IL-10 and IFN-γ at
5 DPI compared with the other groups (P<0.01). The levels of IL-6 were
also significantly increased after intranasal immunization (P<0.01), and
the levels of IFN-γ were increased after intramuscular immunization
(P<0.01). These three acute phase markers (cytokines) were not detected
after 7 DPI (data not shown).
Fig. 1.
Cytokine levels (A, IL-6; B, IL-10; C, IFN-γ) in nasal swabs collected three and 5
days after the first inoculation. Results are presented as the mean ± SEM. The level
of significance is identified by the P value. Capital letters indicate differences at
P<0.01, and small letters indicate differences at
P<0.05
Cytokine levels (A, IL-6; B, IL-10; C, IFN-γ) in nasal swabs collected three and 5
days after the first inoculation. Results are presented as the mean ± SEM. The level
of significance is identified by the P value. Capital letters indicate differences at
P<0.01, and small letters indicate differences at
P<0.05Changes in CD4: The
CD4 and CD8 T lymphocytes in
the lung and hilar lymph nodes (HLNs) were round or elliptical in shape, and the cell
membranes were stained a deep yellow-brown color (Fig.
2). In the lung, the CD4 and
CD8 T lymphocytes were dispersed widely in the alveolar
septum. In the HLNs, the CD4 and
CD8 T lymphocytes were distributed mainly between the
lymphatic nodules, although a few cells were dispersed in the cortical region. The numbers
of CD4 and CD8 T cells increased
significantly in the lung after intramuscular and intrapulmonary immunization compared with
the levels in the other groups (P<0.01).
CD8 T cells increased significantly in the HLNs after
intrapulmonary immunization compared with the levels in the other groups
(P<0.01). The numbers of CD4 and
CD8 T cells in the lung and HLNs did not change after
intranasal immunization compared with those in the control group (Fig. 2).
Fig. 2.
The changes in the distribution and numbers of CD4+ and CD8+ T lymphocytes in the
lung (A, C) and hilar lymph nodes (B, D). Results were
presented as mean ± SEM. The level of significance is identified by the
P value. Capital letters indicate differences at
P<0.01, and small letters indicate differences at
P<0.05.
The changes in the distribution and numbers of CD4+ and CD8+ T lymphocytes in the
lung (A, C) and hilar lymph nodes (B, D). Results were
presented as mean ± SEM. The level of significance is identified by the
P value. Capital letters indicate differences at
P<0.01, and small letters indicate differences at
P<0.05.Changes in IgA- and IgG-secreting cells: The IgA- and IgG-secreting cells
in the nasal mucosa and trachea were distributed in the lamina propria and also surrounding
the tracheal glands, and the lateral surface of the tracheal epithelium was strongly
positively stained for these immunoglobulins (Fig.
3). The areas of IgA- and IgG-secreting cells in the trachea and IgA-secreting cells in
the nasal mucosa increased significantly after intrapulmonary, intranasal; or intramuscular
immunization (P<0.01). The areas of IgG-secreting cells in the nasal
mucosa increased significantly after intranasal or intramuscular immunization with the
attenuated Mhp 168 strain compared with the other groups
(P<0.01).
Fig. 3.
The changes in the distribution and numbers of IgA- and IgG-secreting cells in the
nasal mucosa (A, C) and trachea (B, D). Results are presented as the mean ± SEM. The
level of significance is identified by the P value. Capital letters
indicate differences at P<0.01, and small letters indicate
differences at P<0.05.
The changes in the distribution and numbers of IgA- and IgG-secreting cells in the
nasal mucosa (A, C) and trachea (B, D). Results are presented as the mean ± SEM. The
level of significance is identified by the P value. Capital letters
indicate differences at P<0.01, and small letters indicate
differences at P<0.05.Changes in local Mhp-specific sIgA responses: As shown in Fig. 4, specific anti-Mhp sIgA in the respiratory tract was measured at 7,
14, 21, 28; and 35 DPI. Intrapulmonary, intranasal or intramuscular immunization with the
attenuated Mhp 168 strain significantly increased the levels of specific
sIgA at 7, 14, 21 and 28 DPI compared with those in the control group
(P<0.01), and intrapulmonary immunization with Mhp also
significantly increased the level of sIgA at 35 DPI (P<0.01).
Intrapulmonary immunization with Mhp significantly increased the levels of
sIgA at 7, 21 and 35 DPI compared with the levels in the intranasal and intramuscular
vaccination groups (P<0.01).
Fig. 4.
The S/P values of anti-Mhp-specific SIgA in the nasal secretions collected at 7, 14,
21, 28 and 35 days after the first inoculation. Results are presented as the mean ±
SEM. The level of significance is identified by the P value. Capital
letters indicate differences at P<0.01, and small letters indicate
differences at P<0.05.
The S/P values of anti-Mhp-specific SIgA in the nasal secretions collected at 7, 14,
21, 28 and 35 days after the first inoculation. Results are presented as the mean ±
SEM. The level of significance is identified by the P value. Capital
letters indicate differences at P<0.01, and small letters indicate
differences at P<0.05.
DISCUSSION
Intranasal immunization can prevent the occurrence of respiratory infectious diseases, such
as human influenza [18]. In recent years, intranasal
vaccination has also gained credibility in preventing respiratory infectious diseases in
pigs [1, 4,
16]. In this study, intranasal vaccination
increased the levels of local cellular and humoral immunity in the respiratory tract.
Interestingly, intrapulmonary vaccination induced significantly greater immune responses
than intranasal vaccination. The surface area of the nasal mucosa is very limited and is
only 150 cm2 in humans, whereas the lung has a much larger surface area (almost
140 m2) [14]. There are also a greater
number of capillaries in the lung, which store many lymphocytes, and the number of
lymphocytes in the lung is equal to the number in Peyer’s patches in pigs [15]. The efficacy of a mucosal vaccine is achieved by
prolonging the contact between the antigen and the mucosal surface. Once it enters the lung,
the antigen will remain there for a long time, prolonging the stimulation of the local
mucosal immune response. Therefore, intrapulmonary vaccination is a potentially effective
immunization route, although relevant information about it is very limited [18]. Because Mhp only causes damage to
the respiratory tract, the lung is an optimal target tissue. Therefore, intrapulmonary and
intranasal immunization may offer alternative routes for prevention of the invasion and
colonization of Mhp.Numerous studies have demonstrated a close relationship between the occurrence of
mycoplasmal pneumonia of swine and the production of inflammatory cytokines, and tumor
necrosis factor-α and increased levels of IL-1, IL-6 and IL-10 were detected in the
bronchoalveolar lavage fluid from infected pigs [8].
The numbers of CD4 and CD8 T
lymphocytes are important indicators of cellular immunity levels. Our research has shown
that intranasal immunization and intrapulmonary immunization with the attenuated
Mhp 168 strain alone significantly increased the secretion of IL-6 and
IFN-γ during the early stage after immunization. Intrapulmonary immunization also
significantly increased the secretion of IL-10, and intrapulmonary immunization with
Mhp significantly increased the numbers of CD4+ and
CD8+ T cells present. CD4 T cells mainly elicit
Th1-type cytokine-mediated immune responses and increase the secretion of IFN-γ, whereas
CD8 T cells play a key role in the clearance of pathogens.
IL-6 and IL-10 are Th2-type cytokines in nasal secretions that stimulate the host adaptive
immunity to eliminate pathogens [13, 20, 21]. IFN-γ
secreted in the respiratory tract and lung plays an important role against pathogens and in
macrophage activation, which is effective in the prevention of Mhpinfection [19].The antibodies produced by IgA-secreting cells and IgG-secreting cells seem to play an
important role in protecting animals against infection. IgA-secreting cells, the main
immunocompetent cells in local tissues, have been one of the standard indices used to
estimate mucosal immunity [25]. sIgA is the principal
immunological defense on respiratory mucosal surfaces and prevents effective infection and
colonization of invading pathogens [17]. Increased
local sIgA levels may play an important role in preventing Mhp infection
after intranasal or intrapulmonary immunization in pigs [26]. In a previous study, Dr. Shao demonstrated that intrapulmonary immunization
could provide protection against a challenge with M. hyopneumoniae in pigs
[26].Both intranasal and intrapulmonary vaccinations could increase local cellular and humoral
immunity in the respiratory tract. Interestingly, intrapulmonary vaccination increased the
levels of IFN-γ and sIgA more than intranasal vaccination, which could be explained by the
“common mucosal immune system” [9]. According to this
theory, all mucosal surfaces are linked together as part of the “common mucosal immune
system,” and the induction of immune responses at one mucosal site will spread to other
mucosal sites. For example, immune responses induced in the gut also affect the mammary
gland [3]. Current studies have shown that intranasal
immunization with PRV or PRRSV increases the levels of
specific antibodies and Th1-type cytokines in the lung [4]. The specific IgA-secreting cells generated in nasal-associated lymphoid tissue
can be transferred to other mucosal sites in the respiratory tract to confer wide mucosal
protection [6]. Although these observations suggest
that an immune network exists within the respiratory system, the mechanism of the immune
network is still unclear. A pig model may be a good choice for study of the mucosal immune
network [7, 23].Consistent with Thacker’s report, intramuscular immunization with the attenuated
Mhp 168 strain also induced immune responses in the local respiratory
tract [19], which may be related to the large numbers
of capillaries distributed in the lung. It is easy for Mhp to migrate from
the muscle tissues to the lung via the blood. The lung has a special anatomical position,
located at the juncture of the mucosal immune system and the systemic immune system.
However, intramuscular immunization induced local immune responses at a low level.
Therefore, it is not effective against the invasion of Mhp from the
respiratory tract.In conclusion, we demonstrated that intrapulmonary immunization with the attenuated
Mhp 168 strain induces cellular and humoral immune responses in the local
respiratory tract. Our data indicate that intrapulmonary immunization with
Mhp may be a promising route for vaccinating pigs against
Mhp.
CONFLICTS OF INTEREST
The authors state that they have no conflicts of interest.